The CRI Anna-Maria Kellen Clinical Accelerator

ILIAD-7-US-O-InterLeukin-7 to improve Clinical Outcomes in Lymphopenic Patients with COVID-19 Infection (NCT04426201)

• Anne Rain Brown, PharmD, MD Anderson Cancer Center
• Cassian Yee, M.D., MD Anderson Cancer Center
• Cristina Gutierrez, M.D., MD Anderson Cancer Center (Study chair)
• John Cuenca, M.D., MD Anderson Cancer Center
• Joseph Nates, M.D., MD Anderson Cancer Center
• Marcel van den Brink, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
• Mayoora Muthu, D.O., MD Anderson Cancer Center
• Stephen M. Pastores, M.D., Memorial Sloan Kettering Cancer Center (Study chair)

Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with NSCLC (NCT04093167)

• Adrian Sacher, M.D., Princess Margaret Cancer Centre
• Andrea Fung, M.D., Ph.D., Kingston Health Sciences Centre
• Cheryl Ho, M.D., Vancouver Cancer Centre (Study chair)
• Garth Nicholas, M.D., The Ottawa Hospital Research Institute
• Peter Ellis, M.D., Juravinski Cancer Centre at Hamilton Health Sciences
• Valsamo (Elsa) Anagnostou, M.D., Johns Hopkins University (Study chair)

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER) (NCT03835533)

• Charles Drake M.D., Ph.D., Columbia University
• Julie Graff, M.D., Oregon Health & Science University
• Karen Autio, M.D., Memorial Sloan Kettering Cancer Center
• Kristopher Weintzel, M.D., Angeles Clinic
• Larry Fong, M.D., University of California, San Francisco
• Matt Galsky, M.D., Mount Sinai
• Sumit Subhudhi, M.D., Ph.D., MD Anderson Cancer Center (Study chair)

Treatment with Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer (NCT03651271)

• Alexandra Drakaki, M.D., Ph.D., University of California, Los Angeles
• Apostolia Tsimberidou, M.D., Ph.D., MD Anderson Cancer Center
• Danny Khalil, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
• David Oh, M.D., Ph.D., University of California, San Francisco
• Padmanee Sharma, M.D., Ph.D., MD Anderson Cancer Center (Study chair)
• Saad Khan, M.D., Stanford University
• Stephen Hodi, M.D., Dana Farber Cancer Institute

A Phase 1/2 Study of In Situ Vaccination with Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers (NCT02643303)

• Craig Slingluff Jr., M.D., University of Virginia Health (Study chair)
• Danae Hamouda, M.D., Toledo University
• Elizabeth Gaughan, M.D., University of Virginia Health
• Igor Puzanov, M.D., Roswell Park Cancer Institute
• Keisuke Shirai M.D., Dartmouth University
• Megan Kruse, M.D., Cleveland Clinic       
• Michael Lowe, M.D., Emory University
• Nina Bhardwaj, M.D., Ph.D., Mount Sinai (Study chair)

Results

• Slingluff CL, Dasilva D, Schwarzenberger P, et al. Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors. Journal of Clinical Oncology. 2018.
• Slingluff CL, et al. Abstract #P246 presented at SITC 2017 Annual Meeting (November 8-12, 2017).

A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-Tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects with Advanced Peritoneal Malignancies (NCT02963831)

• Augustin Pimental, M.D., University of Miami
• Danae Hamouda, M.D., University of Toledo
• Dmitriy Zamarin, M.D., Ph.D., Memorial Sloan Kettering Cancer Center (Study chair)
• Emese Zsiros, M.D., Roswell Park Cancer Institute
• Hitendra Patel, M.D., University of California, San Diego
• Linda Duska, M.D., University of Virginia Health

Results

• Zamarin D, et al. Abstract presented at the 2020 ASCO Virtual Scientific Program (May 29-31, 2020).

Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with NSCLC (NCT03164772)

• Hirva Mamdani, M.D., Karmanos Cancer Institute
• Jhanelle Gray, M.D., Moffitt Cancer Center (Study chair)
• Jiaxin Niu, M.D., Banner MD Anderson
• Jonathan Thompson, M.D., Medical College of Wisconsin
• Joshua Sabari, M.D., NYU Langone

Safety and Efficacy of APX005M with Gemcitabine and Nab-Paclitaxel with or without Nivolumab in Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma (NCT03214250)

• Andrew Ko, M.D., University of California, San Francisco
• Eileen O’Reilly, M.D., Memorial Sloan Kettering Cancer Center
• George Ficher, M.D., Stanford University
• Mark O’Hara, M.D., University of Pennsylvania
• Osama Rahma, M.D., Dana-Farber Cancer Institute
• Robert Vonderheide, M.D., D.Phil., University of Pennsylvania (Study chair)
• Robert Wolff, M.D., MD Anderson Cancer Center
• Zev Wainberg, M.D., University of California, Los Angeles

Results

• O’Hara M, O’Reilly E, Varadhachary G et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology. 2021.
• O’Hara M, O’Reilly E, Rosemarie M et al. Abstract CT004. A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Clinical Trials. 2019. (Abstract presented at AACR Annual Meeting 2019, March 29, 2019, by Mark O’Hara.)

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (NCT02431559)

• Blanca Navarro, M.D., University Hospital of Lausanne, Lausanne, Switzerland
• Bradley Monk, M.D., Arizona Oncology
• David O’Malley, M.D., Ohio State University
• George Coukos, M.D., Ph.D., University Hospital of Lausanne, Lausanne, Switzerland (Study chair)
• Paul DiSilvestro, M.D., Woman and Infants Hospital
• Roisin O’Cearbhail, M.D., Memorial Sloan Kettering Cancer Center

Results

• Orcurto A, et al. Successful Treatment with Rituximab of Sjögren’s Syndrome-Associated Organizing Pneumonia in a Patient Treated with PD-L1 Blockade for Ovarian Cancer. Clinical Oncology: Case Report, Vol: 4 Issue: 3, March 10, 2021.
• O’Cearbhaill R.E., et al. Abstract presented at the Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women’s Cancer Webinar Series: Developmental Therapeutics in Gynecological Cancer Webinar. May 28, 2020.
• O’Cearbhaill R.E., Wolfer A. et al. A phase 1/2 study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian… Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. (Abstract presented at ESMO 2018 Congress, Poster display session, 20 October 2018, by Roisin O’Cearbhaill.)

Phase 2 Study of Durvalumab (MEDI4736) in Patients with Glioblastoma (NCT02336165)

• David Reardon, M.D., Dana-Farber Cancer Institute (Study chair)
• Gavin Dunn, M.D., Ph.D., Washington University, St Louis
• Hui Gan, M.D., Austin Hospital, Australia
• Jennifer Clarke, M.D., M.P.H., University of California, San Francisco
• Jorg Dietrich, M.D., Mass General Hospital
• Michael Lim, M.D., Johns Hopkins
• Thomas Kaley, M.D., Memorial Sloan Kettering Cancer Center
• Tim Cloughesy, M.D., University of California, Los Angeles

Results

• Reardon DA, Kaley TJ, Dietrich J, et al. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). Journal of Clinical Oncology. 2019.
• Reardon D, Kaley T, Dietrich J, et al. ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. November 2018;20(suppl_6):vi10-vi10.
• Reardon D, Kaley T, Dietrich J, et al. ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. November 2017;19(suppl_6):vi28-vi28.
• Casey Allie. Checkpoint Inhibitors Show Promise in Glioblastoma. OncLive.com. Published: Friday, Nov 18, 2016.

A Phase 1 Study to Evaluate MEDI4736 in Combination with Tremelimumab (NCT01975831)

• Antoni Ribas, M.D., Ph.D., University of California, Los Angeles   
• Jedd Wolchok, M.D., Ph.D., Memorial Sloan Kettering Cancer Center (Study chair)
• Kunle Odunsi, M.D., UChicago Medicine Comprehensive Cancer Center
• Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center (Study chair)
• Mario Sznol, M.D., Yale University
• Patrick Dillon M.D., University Virginia Health
• Patrick Ott, M.D., Dana-Farber Cancer Institute
• Reva Schneider, M.D., Mary Crowley Cancer Center

Results

• Callahan MK, Odunsi K, Sznol M, et al. Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. Journal of Clinical Oncology. 2018.

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001) (NCT01239134)

• Henry Koon, M.D., University Hospitals
• Dale Shepard, M.D., Ph.D., Cleveland Clinic
• Jedd D. Wolchok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

Results

• Zappasodi R, Sirard C, Li Y, et al. Rational design of anti-GITR-based combination immunotherapy. Nature Medicine. 2019. Rational design of anti-GITR-based combination immunotherapy.
• Koon HB, Shepard DR, Merghoub T, Schaer DA, Sirard CA, Wolchok JD. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. Journal of Clinical Oncology. 2018.

Trials Supported with Reagents

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58) (NCT01585350)

• Craig L. Slingluff Jr., M.D., University of Virginia Health System

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416)

• Immune Design, Seattle, WA

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers (NCT00291473)

• Hiroshi Shiku, M.D., and Shinichi Kageyama, M.D., Mie University School of Medicine, Mie, Japan

A phase I study of concomitant WT1 analog peptide and NY-ESO-1

• David O’Malley, M.D., The Ohio State University Wexner Medical Center
• Paul Sabbatini, M.D., Memorial Sloan Kettering Cancer Center

A phase I study of vaccination with NY-ESO-1 protein mixed with Poly-ICLC, OK-432 (Picibanil®), and ISA-51 (Montanide®) in patients with advanced cancers expressing NY-ESO-1

• Yuichiro Doki, Ph.D., and Hisashi Wada, M.D., Ph.D., Osaka University, Japan

A phase IA/IB study of vaccination with NY-ESO-1 protein, Poly-ICLC, and mogamulizumab in patients with adult T cell leukemia/lymphoma expressing NY-ESO-1

• Yuzuru Kanakura, Ph.D., and Hiroyoshi Nishikawa, M.D., Ph.D., Osaka University, Japan

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence (NCT02334735)

• Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) (NCT01532960)

• Catherine M. Diefenbach, M.D., NYU Langone Medical Center

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus Poly-ICLC in stage IB-IIIA breast cancer

• Patrick M. Dillon, M.D., University of Virginia Health System

A preclinical mouse vaccination experiment to compare the effectiveness of Poly-ICLC to that of the more common QS-21

• Samuel Danishefsky, Ph.D., Memorial Sloan Kettering Cancer Center

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (Mel63; CHAMP) (NCT02425306)

• Craig L. Slingluff Jr., M.D., University of Virginia Health System

Results

• Singluff CL, Zarour HM, Tawbi HA, et al. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. 2021.

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59) (NCT01846143)

• Victor H. Engelhard, Ph.D., and Craig L. Slingluff Jr., M.D., University of Virginia Health System

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients (NCT01079741)

• Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

Phase I/II trial of a long peptide vaccine (LPV8) + Toll-like receptor agonists for resected stage IIB-IV

• Craig L. Slingluff Jr., M.D., University of Virginia Health System

Role of Toll-like receptor 3 in macrophage-mediated programmed cell removal of tumor cells

• Irving Weissman, M.D., Stanford University School of Medicine

Safety and immunogenicity of vaccination with XAGE1b long peptides combined with Poly-ICLC in patients with stage III/IV pulmonary adenocarcinoma

• Christian Taube, M.D., and Maarten L. Zandvliet, Ph.D., Leiden University Medical Center, The Netherlands

Terminated

Nivolumab Ipilimumab in Patients with HyperMutated Cancers Detected in BLood (NIMBLe) (NCT03461952)

Early termination due to low enrollment

• Naiyer Rizvi, M.D., Ph.D., Herbert Irving Comprehensive Cancer Center, Columbia University
• Stephen Chia, M.D., British Columbia Cancer Agency, Canada
• Holger Hirte, M.D., Juravinski Cancer Center, Canada
• Patricia Tang, M.D., Tom Baker Cancer Center, Canada
• Michael Vickers, M.D., MPH, The Ottawa Hospital, Canada

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer (NCT02898116)

Early termination due to the rapidly changing treatment landscape for ALK-positive NSCLC, resulting in low enrollment

• Leena Gandhi, M.D., Ph.D., NYU Langone’s Perlmutter Cancer Center

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant (NCT02716805)

FDA placed on partial hold due to additional data

• Alexander M. Lesokhin, M.D., Memorial Sloan Kettering Cancer Center

• Cancer Immunotherapy Clinical Trials Continue to Grow Globally, Combination Approaches Outpace Monotherapy Trials
  CRI Press Release, February 10, 2022
• Cancer Research Institute and RevImmune Announce Dosing of First Patient in New Phase 2 Study Assessing Therapeutic Benefit of Interleukin-7 in Patients with Cancer and COVID-19
  CRI Press Release, March 30, 2021
• Combination Drug Strategies Gain Ground in Global Immuno-Oncology Pipeline of PD-1 and PD-L1 Clinical Trials
  CRI Press Release, November 11, 2020
• An Initative Led by Parker Institute for Cancer Immunotherapy and Cancer Research Institute Discovers Keys That Could Unlock Better Personalized Treatments to Destroy Cancer
  CRI Press Release, October 9, 2020
• Immunotherapy Drug Development Pipeline Continues Significant Growth In 2020 Despite Global Pandemic Impact
  CRI Press Release, September 18, 2020
• Cancer Research Institute and the Mark Foundation for Cancer Research Launch Research Collaboration to Evaluate Liquid Biopsy for More Accurate and Rapid Assessment of Lung Cancer Patient Response to Immunotherapy
  CRI Press Release, July 22, 2020
• Rapid Growth in Global Development of Cancer Cellular Immunotherapies Highlighted by Latest Report from Cancer Research Institute and GlobalData
  CRI Press Release, May 26, 2020 
• Cancer Research Institute and IQVIA Uncover the Impact of COVID-19 Pandemic on Global Oncology Clinical Trials
  CRI Press Release, May 18, 2020
• Latest Global Immuno-Oncology Landscape Report from the Cancer Research Institute Published in Nature Reviews Drug Discovery
  CRI Press Release, September 27, 2019
• New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint Inhibitors
  CRI Press Release, November 28, 2018
• New International Research Collaboration Explores Blood-Based Biomarker Testing to Identify Cancer Patients that Could Potentially Respond to Immunotherapy
  CRI Press Release, October 2, 2018
• Foundation for the National Institutes of Health and Cancer Research Institute Announce New Collaboration in Cancer Immunotherapy
  CRI Press Release, July 30, 2018
• Ludwig Cancer Research and Cancer Research Institute Launch Clinical Trial Combining Virotherapy and Immunotherapy to Treat Advanced Colorectal and Ovarian Cancers
  CRI Press Release, July 11, 2018
• New Report on the Global Landscape of Cancer Cell Therapy Highlights Robust International Pipeline Marked by Rapid Growth
  CRI Press Release, May 25, 2018
• Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration
  CRI Press Release, January 8, 2018
• The Cancer Research Institute Announces Publication of Comprehensive Immuno-Oncology Landscape Analysis in Annals of Oncology
  CRI Press Release, December 7, 2017
• The Cancer Research Institute and Parker Institute for Cancer Immunotherapy Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy
  CRI Press Release, September 20, 2017
• Immunotherapy Data from CRI Clinical Accelerator to Be Presented at ASCO Annual Meeting
  CRI Press Release, May 23, 2017
• Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology Research
  CRI Press Release, March 28, 2017
• Cancer Research Institute Awards Grant to Develop Powerful Genomic Data Resource for Cancer Immunotherapy Researchers
  CRI Press Release, January 31, 2017
• Ludwig Cancer Research and the Cancer Research Institute Initiate Clinical Trial of a Novel Combination Immunotherapy For Ovarian Cancer
  CRI Press Release, April 6, 2016
• Cancer Research Institute and Ludwig Cancer Research Partner with Targovax to Test Candidate Virotherapy in Early-Phase Clinical Trials
  CRI Press Release, November 18, 2015
• Ludwig Cancer Research and the Cancer Research Institute Evaluate Immunotherapeutic Strategies for Brain Cancer and Other Types of Solid Tumors
  CRI Press Release, July 8, 2015
• Ludwig Cancer Research and Cancer Research Institute Collaborate on Evaluation of VentiRx’s Investigational Immunotherapy
  CRI Press Release, September 3, 2014

• Landscape of cancer cell therapies: trends and real-world data
  Nature Reviews Drug Discovery, June 1, 2022
• Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
  Nature Reviews Drug Discovery, February 10, 2022
• The clinical pipeline for cancer cell therapies
  Nature Reviews Drug Discovery, June 4, 2021
• COVID-19 impact on  oncology clinical trials: a 1-year analysis
  Nature Reviews Drug Discovery, May 17, 2021
• Successful Treatment with Rituximab of Sjögren’s Syndrome-Associated Organizing Pneumonia in a Patient Treated with PD-L1 Blockade for Ovarian Cancer
  Clinical Oncology: Case Report, March 10, 2021
• CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
  The Lancet Oncology, January 1, 2021​
• Combinations take centre stage in PD1/PDL1 inhibitor clinical trials
  Nature Reviews Drug Discovery, November 11, 2020
• Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
  Cell, October 9, 2020
• Immuno-oncology drug development forges on despite COVID-19
  Nature Reviews Drug Discovery, September 18, 2020
• Cancer cell therapies: the clinical trial landscape
  Nature Reviews Drug Discovery, May 26, 2020
• Impact of COVID-19 on oncology clinical trials
  Nature Reviews Drug Discovery, May 18, 2020
• Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
  Journal for ImmunoTherapy of Cancer, April 1, 2020
• Trends in clinical development of PD-1/PD-L1 inhibitors
  Nature Reviews Drug Discovery, November 4, 2019
• Immuno-Oncology Drug Development Goes Global
  Nature Reviews Drug Discovery, September 27, 2019
• The global pipeline of cell therapies for cancer
  Nature Reviews Drug Discovery, May 30, 2019
• Immunotherapy and targeted therapy combinations in metastatic breast cancer
  The Lancet Oncology, March 2019
• The clinical trial landscape for PD1/L1 immune checkpoint inhibitors
  Nature Reviews Drug Discovery, November 28, 2018
• Trends in the global immuno-oncology landscape
  Nature Reviews Drug Discovery, October 19, 2018
• Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
  Annals of Oncology, September 10, 2018
• The global landscape of cancer cell therapy
  Nature Reviews Drug Discovery, May 25, 2018
• Comprehensive analysis of the clinical immuno-oncology landscape
  Annals of Oncology, January 1, 2018
• A Blueprint to Advance Colorectal Cancer Immunotherapies
  Cancer Immunology Research, November 2017
• Translating Science into Survival: Report on the Second International Cancer Immunotherapy Conference
  Cancer Immunology Research, December 2016
• De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute
  Cancer Immunology Research, April 2016
• Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference
  Cancer Immunology Research, January 2016
• T cell assays and MIATA: the essential minimum for maximum impact
  Immunity, July 27, 2012
• The Cancer vaccine Collaborative: a new model of coordinated discovery
  Cancer Immunology Research, 2012
• A methodological framework to enhance the clinical success of cancer immunotherapy
  Nature Biotechnology, October 13, 2011
• Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond
  Cancer Immunology Immunotherapy, January 2011

• COVID’s impact on cancer therapeutics: clinical trial and treatment disruptions
  European Pharmaceutical Review, February 19, 2021
• How COVID-19 Has Impacted Oncology Trials
  Healthcare Tech Outlook, February 11, 2021
• Oncology Centers Examine the Aftermath of COVID-19 on Clinical Trials
  OncLive, June 19, 2020
• Hospitals Are Bracing For a Spike in Cancer Patients as Covid Ebbs
  Bloomberg, June 11, 2020
• COVID-19 slows sign-ups for clinical cancer trials
  Becker’s Hospital Review, May 27, 2020
• IQVIA & Cancer Research Institute Study Reveals Devastating Impact of COVID-19 on Oncology Clinical Trials
  Trial Site News, May 24, 2020
• More Than 200 International Cancer Trials Suspended Due to COVID-19
  Medscape, May 22, 2020
• Changes to Global Oncology Trial Management Due to COVID-19
  Cancer Network, May 20, 2020
• Biopharma Update on the Novel Coronavirus: May 18
  BioSpace, May 18, 2020
• Can Innate Immune Cells Engage in Anti-Tumor Activity?
  OBR, May 2020
• Inovio’s Wild Ride And Real Value
  SeekingAlpha, March 25, 2020
• All chips on immuno-oncology is not a good gamble
  BioCentury, January 13, 2020
• Takeda sees cell, gene therapy in its future. Is it too late?
  BioPharma Dive, November 20, 2019
• Immuno-oncology Boom Doubles Drugs in Development in 2 Years
  Cancer Network, October 11, 2019
• How Technology Is Helping Revolutionize Cancer Treatment
  Forbes, October 4, 2019
• Cancer immunotherapy boom showing no sign of slowdown
  BioPharma Dive, September 27, 2019
• Enough with the me-too drugs. New treatments should be worthy of the people who invest their lives in clinical trials
  STAT, September 4, 2019
• Immunotherapy: Combine and Conquer
  Nature Medicine, May 7, 2015
• CRI and Cancer Immunology
  CenterWatch, April 27, 2015
• Fresh funds in hand, VentriRx joins AstraZeneca, Ludwig and CRI for combo immuno-oncology study
  Fierce Biotech, September 3, 2014

• Defining Resistance to Treatment with Anti-PD-1/PD-L1 Immunotherapy
  CRI Blog, April 8, 2020
• CRI-Sponsored Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer
  CRI Blog, March 31, 2019
• Advocating for Innovative Clinical Trial Design
  CRI Blog, April 25, 2018
• Immunotherapy in the Fast Lane: CRI’s Clinical Accelerator Takes Off
  CRI Blog, January 7, 2014